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I. ABSTRACT 
Background and objectives 
Breast cancer is one of the most common malignancies among women in the United States. 
Women residing in the state of Kentucky have breast cancer incidence and mortality rates greater 
than the national average. Recent studies suggest an association between breast cancer 
subtypes/hormone receptor (HR) status and the risk of recurrence and the onset of subsequent 
primary cancer, however, limited research has focused on Kentucky or its Appalachian region. 
Investigating these associations may potentially save lives by providing information that can be 
used in breast cancer education in Kentucky, assessing the population at greater risk of 
recurrence and subsequent cancer (by subtypes), increasing screening in the population at risk, 
and developing tailored interventions for each region. Therefore, the purpose of this study was to 
examine the relationship between breast cancer subtypes/hormone receptor status and the risk of 
recurrence and/or the risk of subsequent cancers among women in Kentucky with a specific 
focus on disparities in these risks that may exist between women living in Appalachia compared 
to non-Appalachia.  
 
Methods 
The analysis used data from the Kentucky Cancer Registry (KCR), specifically females ages 18 
or older diagnosed with primary breast cancer between 2004 and 2016. A retrospective cohort 
study was conducted to assess the risk of (1) subsequent primaries and (2) recurrence among 
each breast cancer subtype/HR status. Subjects’ maximum follow-up period for the cohort study 
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was five years or 60 months. To assess the relationship between breast cancer subtypes and the 
risk of recurrence and/or the risk of subsequent cancers, a series of Cox regression analyses were 
performed. The study was conducted in two parts: first, we analyzed data from women diagnosed 
between 2004 and 2016, examining HR status as a risk factor and second, we focused on women 
diagnosed between 2011 and 2016, examining breast cancer subtype as a risk factor. 
Results 
Between 2004 and 2016, it was observed that women with estrogen receptor-positive (ER+ only) 
breast cancer had a lower risk of subsequent primaries compared to women with HR+ (estrogen 
receptor-positive [ER+] and progesterone receptor-positive [PR+]) breast cancer (HR:0.85, 95% 
CI: 0.74,0.96). When stratified by Appalachian status, a similar trend was only seen among non-
Appalachian women (HR:0.80, 95% CI: 0.69,0.94). In examining recurrence outcomes, women 
with ER+, PR+, and HR-negative (HR-) breast cancer had an increased risk compared to women 
with HR+ breast cancer with hazard ratios of 1.61 (1.28, 2.03), 2.09 (1.57,3.96), and 3.16 (2.64, 
3.79), respectively. Clinically significant disparities in the risk of recurrence between 
Appalachian and non-Appalachian women were also observed for ER+ (1.49 vs. 1.84), PR+ 
(2.47 vs 2.30), and HR- (2.07 vs. 2.58) breast cancer subtypes.  For the focused analysis (2011-
2016), women with Luminal A and B subtypes had a lower risk of recurrence compared to 
human epidermal growth factor receptor 2 (HER2) enriched and triple negative in both the 
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overall and stratified analyses. Also, non-Appalachian women with Luminal B had a reduced 
risk of subsequent cancers (HR:0.76, 95% CI: 0.59,0.99) compared to non-Appalachian women. 
Conclusion 
Among this population-based sample of women in Kentucky, breast cancer subtype/HR status 
was associated with the risk of subsequent primaries and recurrence. There were also noted 
disparities in the risk of recurrence between women who live in Appalachian Kentucky and 
women living in non-Appalachia. Women living in Appalachian Kentucky tended to have lower 
risk of recurrence compared to women living in non-Appalachia for similar subtypes adjusted for 
several clinical, behavioral, and insurance-related variables.  
 
II. Introduction  
Breast cancer is a disease that is characterized by the proliferation of malignant breast cells.  It is 
the most common malignancy in women worldwide, and the most common cause of cancer-
related death among women. It is estimated that 2.1 million new cases and 626,679 deaths will 
occur worldwide in 2018 1. In the United States (U.S.), breast cancer is the most common type of 
cancer and the second most common cause of death; specifically, in 2018 is estimated that there 
will be 266,120 new cases of female breast cancer and 40,920 deaths will occur as a result of the 
disease 2. Although the exact cause of breast cancer is unknown, multiple risk factors have been 
associated with its development including tobacco use, diet, alcohol use, age at menarche, parity, 
breast feeding, age at menopause, and endogenous hormones 3-6. 
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Breast cancer is often subdivided into four main molecular subtypes based on the genes 
expressed by the malignant breast cells: Luminal A, Luminal B, human epidermal growth factor 
receptor 2 (HER2) enriched, and basal-like (triple negative) 7,8. Luminal A subtype is 
characterized by positive hormone receptors (HR) (estrogen-receptor [ER] and/or progesterone-
receptor [PR]), negative HER2, and low levels of the protein Ki-67. Luminal B subtype is 
characterized by positive HR (ER+ and/or PR+), and either HER2 positive or HER2 negative 
with high levels of Ki-67 9. A cancerous breast cell is considered HER2-enriched or 
overexpressed when it is HR negative (ER- and PR-) and HER2 positive 10. The triple negative 
subtype is characterized by HR negative cancerous breast cells (ER- and PR-) and negative 
HER2 11,12.  
 
Recent studies suggest an association between breast cancer subtype/hormone receptor status and 
outcomes such as recurrence and subsequent primaries13-16. Most of these studies have involved 
nationwide or global analyses, which can introduce ecological fallacies 17,18. Few studies have 
investigated the association in specific U.S. states or among specific geographic, medically 
underserved populations such as Appalachian Kentucky. In addition, current studies have only 
focused on contralateral breast cancer as a subsequent cancer rather than any other type of 
subsequent cancers 13,14. Therefore, this study aimed to examine the relationship between breast 
cancer subtypes and the risk of recurrence and/or the risk of any subsequent cancers in the state 
of Kentucky. Furthermore, the study investigated the potential disparities in these risks between 
women living in the 54-county, primarily rural Appalachian region of the state compared to 
women residing in non-Appalachia (66 counties). Based on rural-urban continuum codes, 
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Kentucky is approximately 40% rural, compared to the Appalachian region, which is over 80% 
rural 19-22. Rural women in the state have notable breast cancer disparities (e.g., increased 
mortality, late stage diagnoses) compared to non-rural women. These disparities may be due to 
geographic isolation, high prevalence of poverty, barriers to healthcare and mammography 
services (e.g., transportation, educational ascertainment / literacy, social support, stigma) 20,22,23.  
Exploring the impact of breast cancer subtypes on the outcomes of interest may further explain 
the breast cancer inequities observed in the Appalachian region.  
 
LITERATURE REVIEW 
The following review is a synopsis of the current knowledge of the association between breast 
cancer subtype/hormone receptor status and recurrence and/or subsequent primary in the 
published literature. This review gathers empirical and theoretical knowledge from peer-
reviewed journal articles, books, governmental fact sheets, websites, and national and 
international organizational reports in the field of epidemiology, medicine, oncology, public 
health, and physiology.  Relevant literature was found through the following databases: Google 
Scholar, Web of Science, and PubMed using keywords or phrases such as breast cancer, breast 
cancer recurrence, breast cancer subtypes, multiple primary, Appalachia, Kentucky and 
subsequent cancer. Additional material cited in relevant works was included in the literature 
review.  The literature review is divided into the following sections: breast cancer, subtypes, 
recurrence and subsequent primary tumors, and breast cancer in Kentucky.  
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Breast cancer 
Breast cancer refers to malignant or compromised cell proliferation originating from breast tissue 
3,24. Breast cancer usually originates from the lobule, the gland the makes milk (lobular 
carcinoma) or the inner lining of milk ducts, a thin tube that carries milk from the breast lobule 
to the nipple (ductal carcinoma) 25-28. Breast cancer cells can metastasize through the 
bloodstream, channels to nearby lymph nodes, and/or invade regional and distant organs 24,29. 
Breast cancer starts the carcinogenesis process by the random and/or induced (e.g., 
electromagnetic or nuclear radiation, viruses, environmental exposure, biological hazards or 
food) modification or mutation of normal cells’ DNA, RNA, tumor suppressor genes, DNA 
repair genes, and/or the creation of oncogene (from proto-oncogenes) 30.   
 
Oncogenes and tumor suppressor genes are the two principal genes that play a major role in the 
carcinogenesis process. Oncogenes are mutated proto-oncogenes (i.e., normal proteins involved 
in cell cycle progression) that are abnormally active and induce proliferation. Tumor suppressor 
genes regulate or inhibit the proliferation of normal and mutated cells by slowing down cell 
division, repairing DNA mistakes, or ordering cells to die (a process known 
as apoptosis or programmed cell death) 31-33. When tumor suppressor genes and/or proto-
oncogenes of normal cells are mutated, the neoplastic cells acquire the ability to continuously 
proliferate, evade apoptosis, grow with unlimited potential, evade the immune system, and 
become independent from growth factors or  metastasize 34. HER2, Breast Cancer type 1 
susceptibility protein (BRCA1), Breast Cancer type 2 susceptibility protein (BRCA2), and p53 
are examples of oncogenes and tumor suppressor genes that play a major role in breast cancer 
carcinogenesis.  
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Subtypes 
Breast cancer is classified into four main molecular subtypes that are based on the protein 
expressed by the neoplastic cells. The molecular subtypes include Luminal A, Luminal B, HER2 
enriched, and triple negative. These breast cancer subtypes play a major role in the cancer’s 
virulence, growth, metastatic ability, and responsiveness to treatment 7,9-11.  
Luminal A breast cells are characterized by the presence of steroid HR (estrogen and/or 
progesterone), meaning that the cancerous cells grow faster in the presence of estrogen or 
progesterone. In addition, Luminal A cells have a normal amount or no HER2. Lastly, Luminal 
A cells have a low expression of antigen Ki-67, a protein that indicates how fast cells are 
dividing. Luminal A cells tend to grow slowly, be less aggressive, and have low recurrence rates. 
They are also more responsive to endocrine treatments, thus people with Luminal A breast 
cancer tend to have a high survival rate 35. Luminal B breast cancer cells are also HR+, but differ 
from Luminal A breast cancer cells by the presence of an excessive amount of HER2. Neoplastic 
cells can also be categorized as Luminal B when they are HR+, have a normal amount or no 
HER2, and have high Ki67 level. Luminal B breast cancers have a significantly higher 
proliferation rate and worse prognosis than Luminal A 36.  HER2 enriched or overexpressed 
breast cancer cells are HR-, meaning the neoplastic cell growth is not triggered or enhanced by 
the presence of estrogen or progesterone, and have an excessive amount of HER2. They grow 
and spread more aggressively than Luminal A and B subtypes. HER2 enriched breast cancer 
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cells are also more likely to be high grade and node positive than the Luminal subtypes37. Basal 
like or triple negative are breast cancer cells that are both HR- and HER2 negative. They have a 
high histologic grade, are very aggressive, and have the worst prognosis of all subtypes 11,12. 
Numerous studies have linked breast subtype to the risk of recurrence and/or second primary 
15,16. 
Recurrence 
Cancer recurrence refers to the reemergence of a cancer after a period of remission. It is 
potentially caused by the survival of a small number of cancerous cells after treatment that may 
not show up in tests during the remission period. The Surveillance, Epidemiology and End 
Results (SEER) program of the National Cancer Institute (NCI) considers a new cancer of the 
same site or with the same histology as an earlier one as the same primary cancer if diagnosed 
within 60 months, unless the medical record specifically states that it is recurrent or metastatic 
disease (https://seer.cancer.gov/tools/mphrules/mphrules_flowchart.pdf). Cancer recurrence can 
be local (in or around the initial location), regional (in the lymph nodes or tissue near initial 
cancer), or distant ( in organs and far from the initial location) 38. Current studies have 
investigated and established an association between breast cancer subtypes and the risk of breast 
cancer recurrence 15,16. Luminal A tumors are associated with the lowest risk of recurrence rates 
while basal-like tumors have the highest risk; Luminal B and HER2 have intermediate risks 
15,16,37,39-42.  
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Subsequent Primary Tumors 
A subsequent primary tumor is a new, unrelated, and histologically different primary  
cancer in a person who has a previously diagnosed cancer. Among women with breast cancer as 
a first primary cancer, the incidence of multiple primaries has been reported in the range of 4.1% 
43  to 16.4% 44. Recent epidemiologic studies have suggested an association between breast 
cancer HR status and the risk of subsequent primary tumors 13,14. One relevant study used the 
National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) database 
to examine the risk of a second primary (contralateral breast cancer) among 4,927 women 
diagnosed with a first primary breast cancer between 1992 and 2004. The exposure and outcome 
of interest were HR status and the risk of contralateral breast cancer, respectively. The study 
found that women with a first primary HR+ breast tumor had an elevated risk of contralateral 
primary breast cancer compared to the general population adjusted for age, race, and calendar 
year (SIR = 2.22, 95% CI = 2.15, 2.29). Also, women with HR- breast tumors had a statistically 
significantly higher risk of a second contralateral breast cancer diagnosis than women with HR+ 
breast tumors (SIR = 3.57, 95% CI = 3.38, 3.78) 14. The vast majority of literature available on 
the association between HR status and subsequent primary cancers has focused on contralateral 
breast cancer as the subsequent cancer 13,14. Few have looked at the risk of any other subsequent 
cancers. There is a need to further investigate the potential association between breast cancer 
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subtypes and the risk of either breast cancer recurrence or subsequent primary cancer. This study 
will provide additional elucidation on this association by focusing on the state of Kentucky.  
Breast cancer in Kentucky 
The age-adjusted incidence rate of invasive female breast cancer in Kentucky during 2012-2016 
is 126.3 per 100,000 (Figure 1). The incidence rate was different by Appalachia status. In 
Kentucky’s Appalachian region, the incidence rate was 118.1/100,000 [95% CI: (114.5, 121.7)], 
while in Kentucky’s non-Appalachian region the rate was 129.4/100,000 [(95% CI: 
(127.1,131.98)] in the same period. Furthermore, the incidence of Luminal A breast cancer in 
Kentucky’s Appalachian region was 73.9/100,000 [95% CI: (70.8, 77.1)], while in Kentucky’s 
non-Appalachian region the rate was 86.0/100,000 [(95% CI: (83.9,88.1)] (Figure 3). Luminal B 
breast cancer incidence rate in Kentucky’s Appalachian region was 11.5/100,000 [95% CI: 
(10.2,12.8)], while in Kentucky’s non-Appalachian region the rate was 12.5/100,000 [(95% CI: 
(11.7,13.3)] (Figure 4). HER2-enriched breast cancer incidence rate in Kentucky’s Appalachian 
region was 5.6/100,000 [95% CI: (4.7,6.5)], while in Kentucky’s non-Appalachian region the 
rate was 5.3/100,000 [(95% CI: (4.8,5.9)] (Figure 5). Triple negative breast cancer incidence rate 
in Kentucky’s Appalachian region was 15.4/100,000 [95% CI: (14.0,17.0)], while in Kentucky’s 
non-Appalachian region the rate was 14.3/100,000 [(95% CI: (13.5,15.2)] (Figure 6).  
Although the overall incidence rate of female breast cancer is lower in Appalachian Kentucky as 
compared to non-Appalachian Kentucky, the mortality rate is higher. The mortality rate among 
non-Appalachian women was 20.7/100,000 (95% CI: (19.1,21.7) versus 23.2/100,000 (95% CI: 
(21.5,25.1) among Appalachian women (Figure 2). Lower breast cancer incidence and higher 
mortality rates in Appalachian KY may be explained by documented risk factors and inequities 
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in social determinants of health among Appalachian populations such as geographic isolation, 
access to care barriers, (e.g., transportation, under or uninsured, educational ascertainment / 
literacy, social support, stigma), poor quality of life outcomes, cultural beliefs, significant 
socioeconomic barriers, later stage diagnoses, co-morbidities, and/or under-screening 20-23,45.  
  
III. METHODS 
Study Design 
 
This study is a retrospective cohort focused on women diagnosed with invasive breast cancer as 
a first primary between 2004 and 2016 in Kentucky using KCR data. Study subjects were 
followed for a maximum of 60 months from the date of the diagnosis of the first primary to the 
onset of a subsequent primary cancer diagnosis and the recurrence of the first primary. The study 
sample was then stratified by Appalachian status (Appalachian vs. non-Appalachian based on 
county of residence; https://www.arc.gov/appalachian_region/CountiesinAppalachia.asp) to 
observe its impact on the distribution of the exposure of interest (breast cancer subtypes) and the 
outcomes of interest (recurrence and subsequent primary cancer). The study was limited to breast 
cancer cases among women ages 18 years or older with known HR status (estrogen and/or 
progesterone receptors). Breast cancer cases diagnosed at autopsy or death certificate only were 
excluded from the cohort. 41,391 women were diagnosed with malignant breast cancer (first 
primary) between 2004 and 2016 in Kentucky. From this sample, 31,058 satisfied the inclusion 
criteria and composed the analytic cohort. 8,150 women resided in Appalachia and 22,908 
resided in non-Appalachia. 
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Data Source 
 
This study used KCR data from women ages 18 years or older diagnosed with a primary 
malignant breast cancer between 2004 and 2016. KCR is the official population-based cancer 
registry of the Commonwealth of Kentucky, part of NCI’s SEER program, and a longstanding 
member of the Centers for Disease Control and Prevention’s National Program of Cancer 
Registries. KCR performs ongoing systematic collection, analysis, and interpretation of 
population-based cancer data in the state of Kentucky. More information about KCR can be 
obtained at https://www.kcr.uky.edu/about.php.   
 
 
Demographic Covariates  
 
The demographic characteristics of the cohort were composed of well-studied risk factors for 
cancer in general, and breast cancer in particular, such as age at diagnosis, stage of the first 
primary, race, tobacco use, family history (of the first primary), menopausal status, and insurance 
type. Age at diagnosis was categorized as follows: <35 years, 35-44, 45-54, 55-64, 65-74, 75-84, 
and 85+). Stage at diagnosis of the first primary was categorized in four groups following SEER 
Summary Stage 2000 (localized, regional, distant, and unknown). Race was divided into black, 
white, other and unknown. Tobacco use, family history, and menopausal status each had three 
categories (Yes, No, and Unknown).  Insurance status was categorized into not insured, insured 
(people with private, military, and/or veteran insurance), Medicaid, Medicare, and unknown.  
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Exposure Assessment  
 
The exposure of most interest for this study was breast cancer subtypes. Because KCR lacked 
data on HER2 prior to 2009, the exposure of interest for women diagnosed with breast cancer 
between 2004 and 2016 was HR status (ER and PR). The study established four levels of 
exposure: ER+ only, PR+ only, ER+ and PR+, and ER- and PR-. 
 
Breast cancer cases were categorized as ER+ only when cancerous breast cells grew faster in 
response to estrogen level only, PR+ only when cancerous breast cells grew faster in response to 
progesterone level only, ER+ and PR+ when cancerous breast cells grew faster in response to 
both estrogen and progesterone levels, and ER- and PR- when cancerous cells grew 
independently of hormone level (progesterone or estrogen). 
 
In the focused analysis, females diagnosed with breast cancer between 2011 and 2016, the 
exposure of interest was the combination of HR status and HER2 status, following the typical 
classification of breast cancer subtype. The subtypes were categorized independently of Ki67 
levels because the KCR lacked data on this variable. The five levels of exposure for the focused 
analysis were Luminal A, Luminal B, HER2 enriched, triple negative, and other. Subjects were 
categorized as Luminal A when cancerous breast cells were ER+ and/or PR+, and HER-; 
Luminal B when cancerous breast cells were ER+ and/or PR+, and HER2+; HER2 enriched 
when cancerous breast cells were ER-, PR-, and HER2+; triple negative when cancerous breast 
cells were ER-, PR-, HER2-, and Other when cancerous breast cells had borderline results, 
missing one or more test(s), or not documented.  
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Outcome Assessment  
 
The outcomes of interest of the study were: (1) the onset of subsequent primary cancer and (2) a 
recurrence within five years or 60 months from being diagnosed with breast cancer.     
 
Statistical Analysis                       
All statistical analyses were performed using SAS version 9.4. Descriptive statistics of the 
relevant variable comparing Appalachian / non-Appalachian status were conducted using a t-test 
for continuous variables and chi-square for categorical variables. A series of univariate Cox 
proportional-hazard regressions were performed to assess the impact of potential cofounders and 
effect modifiers on the risk of subsequent cancer and recurrence. Multivariate Cox proportional-
hazard regressions assessed the association between breast cancer cells HR status or subtypes 
with the hazard of subsequent cancer or recurrence by region of residence. 
 
IV. RESULTS 
ER/PR Status and Risk of Subsequent Primary Cancer and Recurrence (2004-
2016) 
The distribution of demographic characteristics was statistically different for women residing in 
Appalachia compared to women in non-Appalachia for the following variables: age at diagnosis, 
stage of the first primary, race, tobacco use, family history, menopausal status, number of live 
births, HR status, and insurance status (Table 1). In both geographic groups, whites were the 
majority (98.07% of Appalachian subjects were whites vs. 90.23% among non-Appalachian). 
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There was a higher prevalence of tobacco use among non-Appalachian residents than 
Appalachian residents (36.77% vs. 33.35%). Post-menopausal subjects were more prominent in 
non-Appalachia compared to Appalachia (65.03% vs. 60.97%). The prevalence of localized 
breast cancer was higher among non-Appalachian subjects compared to Appalachian subjects 
(64.57% vs. 60.87%). The distribution of health insurance coverage was noticeably different 
between the two geographic groups. Non-Appalachian subjects had a higher prevalence of 
private health insurance than Appalachian subjects (51.04% vs. 39.77%), while Appalachian 
subjects had a higher prevalence of Medicaid coverage (13.07% vs. 6.69%). Non-Appalachian 
residents had a higher burden of ER+ and PR+ tumors in the overall analysis (68.37% vs 
66.44%) than Appalachia residents. The distribution of the outcome of interest (recurrence and 
subsequent cancer) was not statistically different between Appalachians vs non-Appalachians. 
After the 60 months follow-up period, 6% of the cohort were diagnosed with a recurrence of 
their first primary after remission and 8% had the onset of subsequent primaries with no 
statistically significant difference between the two geographic groups (Table 2). Breast cancer 
was the most common type of subsequent primary cancer among Appalachian residents 
(45.51%) and non-Appalachian residents (53.95%) (Table 3). 
Univariate analysis results are provided in Table 4. Stage of the first primary, family history, 
menopausal status, age at diagnosis, tobacco use, and insurance status had positive associations 
with the risk of outcomes of interest (p<0.05). The multivariable Cox regression model results 
are shown in Table 5. 
Subsequent primary 
In the unstratified analysis (Appalachian + non-Appalachian), subjects who were ER+ only had 
a lower risk of subsequent cancer (HR:0.85, 95% CI: 0.74,0.96) than subjects who were ER+ 
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and PR+.  In the stratified analysis, non-Appalachian ER+ only subjects had a lower risk of 
subsequent cancer (HR:0.80, 95% CI: 0.69,0.94) compared to non-Appalachian subjects who 
were ER+ and PR+. Among Appalachian residents there were no statistically significant 
differences among subtypes.  
Recurrence 
For the recurrence outcomes, disparities in the risk associated with each subtype were observed. 
Compared to ER+ and PR+, Appalachian residents had the following increased hazard for ER+ 
only, PR+ only, and ER- and PR- (1.49, 2.47, 2.07, respectively). Non-Appalachian residents 
had the following increased hazard for ER+ only, PR+ only and ER- and PR-: 1.84, 2.30, 2.58, 
respectively. 
 
ER/PR/HER2 Status and Risk of Subsequent Primary Cancer and Recurrence 
(2011-2016) 
Part two of the study focused on women with breast cancer diagnosed between 2011 and 2016 
and observed the impact of breast subtypes (HR + HER2 status). Non-Appalachian residents had 
a higher burden of Luminal A in the focused analysis (69.55% vs 66.12%) than Appalachia 
residents (Table 6). Table 7 lists the results of this focused analysis.  
Recurrence 
Compared to Luminal A subjects, Luminal B, HER2 enriched, and triple negative women had 
higher risks of recurrence with the following hazard ratios: 1.61, 2.09, 3.16, respectively (p 
<0.05). After stratifying by Appalachian status, only triple negative cases had a statistically 
significant increased risk among Appalachian women. For non-Appalachian women, those with 
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Luminal B, HER2 enriched, and triple negatives subtypes had increased hazard of 1.69, 2.57, and 
3.35, respectively (p<0.05) compared to Luminal A subtypes.  
Subsequent primary  
Among non-Appalachian residents, those women with Luminal B had a reduced risk of 
subsequent cancers (HR:0.76, 95% CI: 0.59,0.99). 
 
V. DISCUSSION 
The goal of the study was to examine the relationship between breast cancer HR/subtypes and 
the risk of recurrence and/or the risk of subsequent cancers among women in Kentucky. 
Additionally, the study investigated disparities in the mentioned-above outcomes between 
women living in Appalachian Kentucky compared to women living in non-Appalachian 
Kentucky. For the risk of recurrence outcome, the observed results were consistent with the 
current literature 16,39-42 and showed that women with Luminal A and B subtypes had a lower risk 
of recurrence compared to women with triple negative and HER2 enriched breast cancers. This is 
due to the fact that Luminal A and B cancerous cells are HR+ (their growth or proliferation is 
triggered by the presence of estrogen or progesterone).  In order to control their growth and 
proliferation, patients often receive endocrine therapy to block the HR, thus metastasis can be 
controlled more effectively. The triple negative and HER2 enriched subtypes, on the other hand, 
tend to spread more aggressively and are unresponsive to hormone therapy. When cancerous 
breast cells spread to distant organs, they tend to re-emerge even after mastectomy or other 
treatment 39. After a period of remission, cancerous cells that metastasized to distant regions and 
were not killed or controlled by treatment can proliferate again 46,47. When we looked at HR 
status independently of HER2 status (2004-2016 analysis), it was also observed that ER+ and 
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PR+ subjects had a lower risk of recurrence than those positive to only one HR or those negative 
to both HR. Approximately 80% of breast cancers are ER+ and 65% of the  ER+ tumors are also 
PR+ 48. Because they are so prevalent, current endocrine treatment has been designed to target 
estrogen receptors primarily and progesterone secondarily to control the growth and proliferation 
of HR+ neoplastic cells. HR- (ER- and PR-) tumors grow and spread independently of the 
presence of estrogen or progesterone, as is the case with triple negative tumors, thus increasing 
the risk of recurrence.   
 
ER+ only and Luminal B non-Appalachian subjects had reduced risk of subsequent cancers 
compared to non-Appalachian ER+ and PR+ and Luminal B subjects (p<0.05). One potential 
explanation of the reduced risk is that both respond to hormone therapy49. The majority of 
subsequent tumors among these women were breast cancer. ER+ and Luminal B women often 
receive endocrine therapy to treat their cancers. The treatment can have a protective effect 
against subsequent primaries that are also estrogen or HR+. The association between breast 
cancer subtypes and the risk of subsequent cancer needs to be further investigated. 
 
Disparities between Appalachian and non-Appalachian women in the risk of recurrence and/or 
subsequent cancer can be partially explained by the inequity in access to quality healthcare 
and/or differences in cancer mortality rates between the two regions. Previous investigations 
suggest that Appalachian Kentuckians experience geographic isolation, a high prevalence of 
poverty, considerable barriers to healthcare (e.g., transportation, education ascertainment / 
literacy, social support, stigma), and later stages at diagnosis 20-22,45.  These regional disparities 
are a potential reason why breast cancer incidence rates are lower and mortality rates are higher 
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among Appalachia residents compared to non-residents. Also, non-Appalachian residents with 
breast cancer live longer or have a lower risk of death than Appalachian residents 20,22,23,45. By 
living longer, they may live long enough to have subsequent cancers and/or recurrence. 50,51 
 
This research adds value to the epidemiology field by identifying which subtypes/HR status 
increases the risk of recurrence and subsequent cancer. In addition, the results of this 
investigation may potentially save lives by providing information that can be used in breast 
cancer education in Kentucky, assessing the sub-population at greater risk of recurrence and 
subsequent cancer (by subtypes), increasing screening in the sub-population at risk, and 
developing tailored interventions or communications messaging for each region. 
 
This study had a number of limitations. The first limitation is that some subjects’ demographic 
characteristics had “unknown” data. For example, 17.49% of the study sample had unknown 
tobacco use status, 50.30% of the women had unknown number of live births, 22.15% had 
unknown family history of the breast cancer, and 14.82% of subjects had unknown menopausal 
status. The “unknown” data potentially introduced non-differential bias and biased results toward 
the null. This can be observed in that some known risk factors such as family history or number 
of children had marginal or no statistically significant impact on the risk of the outcomes. 
Another potential limitation is the lack of data about occupations, socioeconomic status, 
comorbidities, and alcohol use. Not adjusting for these factors could have confounded or 
modified the results. The KCR dataset lacked information on Ki-67 protein, which may have 
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impacted the accuracy of the way breast cancer subtypes were defined. Lastly, the study did not 
adjust for the treatment receive by each subject. As mentioned earlier, cancer treatment in 
general and endocrine therapy in particular is often associated with lower risk of recurrence 46,47. 
Not controlling for it could have confounded or modified the results. 
 
In conclusion, breast cancer subtype/HR status is associated with the risk of subsequent 
primaries and recurrence. Also, there are disparities in the risk of recurrence between 
Appalachian and non-Appalachian women in Kentucky. Women in Appalachian KY had lower 
risk of recurrence than their non-Appalachian KY counterparts for similar subtypes adjusted for 
family history, menopausal status, age at diagnosis of the first primary, stage, tobacco use, and 
insurance status. Biologic differences may be responsible for differences seen in 
recurrence/subsequent primaries between Appalachian resident and non-Appalachian residents.  
A future direction of the study is a genome sequencing analysis of collected breast cancer tissues 
of Appalachian and non-Appalachian women to assess the potential biological or epigenetic 
differences between the two sub-populations that may explain the observed disparities in 
Kentucky 
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VIII. APPENDIX 
 
Table 1.  Descriptive statistics of the cohort of Kentucky women diagnosed with breast cancer 
between 2004-2016 and satisfied the inclusion criteria.   
 
 
 Kentucky 
N= 31,058 
Appalachia  
N= 8,150 
Non-Appalachia  
N= 22,908 
p-value 
Age at diagnosis 
< 35 
35 – 44 
45 – 54 
55 – 64 
65 – 74  
75 – 84 
85 + 
 
591 (1.90%) 
2,956 (9.52%) 
6,752 (21.74%) 
8,489 (27.33%) 
7,061 (22.73%) 
4,001 (12.88%) 
1,208 (3.89%) 
 
156 (1.91%) 
751 (9.21%) 
1,690 (20.74%) 
2,340 (28.71%) 
1,949 (23.91%) 
992 (12.17%) 
272 (3.34%) 
 
435 (1.90%) 
2,205 (9.63%) 
5,062 (22.10%) 
6,149 (26.84%) 
5,112 (22.32%) 
3,009 (13.14%) 
936 (4.09%) 
 
 
 
<0.0001 
Stage 
Localized 
Regional 
Distant 
Unknown 
 
19,752 (63.60%) 
9,425 (30.35%) 
1,731 (5.57%) 
150 (0.49%) 
 
4,961 (60.87%) 
6,808 (29.72%) 
1,206 (5.26%) 
47 (0.58%) 
 
14,791 (64.57%) 
2,617 (29.72%) 
525 (6.44%) 
103 (0.45%) 
 
 
<0.0001 
Subtypes 
ER+ Only 
PR+ Only 
ER+ and 
PR+ 
ER- and PR- 
 
3,532 (11.37%) 
344 (1.11%) 
21,080 (67.87%) 
 
6,102 (19.65 %) 
 
975 (11.96 %) 
99 (1.21 %) 
5,418 (66.44%) 
 
1,658(20.34%) 
 
2,557 (11.16%) 
245 (1.07%) 
15,662 (68.37%) 
 
4,444 (19.40%) 
 
 
0.0152 
Race 
Black 
White 
Other 
Unknown 
 
2,126 (6.85%) 
28,664 (92.29%) 
182 (0.59%) 
86 (0.28%) 
 
115 (1.41%) 
7,993 (98.07%) 
11 (0.13%) 
31 (0.38%) 
 
2,011 (8.78%) 
20,671 (90.23%) 
171 (0.75%) 
55 (0.24%) 
 
 
<0.0001 
Tobacco user 
No 
 
15,107 (48.64%) 
 
3,876 (47.56%) 
 
11,231 (49.03%) 
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Yes 
Unknown 
11,141 (35.87%) 
4,810 (15.49 %) 
2,718 (33.35%) 
1,556 (19.09%) 
8,423 (36.77%) 
3,254 (14.20%)  
<0.0001 
Family History 
Yes 
No 
Unknown 
 
10,419 (33.55%) 
14,487 (46.65%) 
6,152 (19.81%) 
 
2,545 (31.23%) 
3,439 (42.20%) 
2,166 (26.57%) 
 
7,874 (34.37%) 
11,048 (48.23%) 
3,986 (17.40%) 
 
 
<0.0001 
Menopausal Status 
Pre 
Post 
Unknown 
 
6,482 (20.87 %) 
19,866 (63.96%) 
4,710 (15.17%) 
 
1,729 (21.21%) 
4,969 (60.97%) 
1,452 (17.82%) 
 
4,753 (20.75%) 
14,897 (65.03%) 
3,258 (14.22%) 
 
 
<0.0001 
Insurance 
Not Insured 
Insured 
Medicaid 
Medicare 
Unknown 
 
687 (2.21%) 
14,933 (48.08%) 
2,598 (8.37%) 
12,585 (40.52 %) 
255 (0.82%) 
 
229 (2.81%) 
3,241 (39.77%) 
1,065 (13.07%) 
3,505 (43.01%) 
110 (0.63%) 
 
458 (2.00%) 
11,692 (51.04%) 
1,533 (6.69%) 
9,080 (39.64%) 
145 (0.63%) 
 
 
 
<0.0001 
• Follow-up period 5 years maximum 
• Bold: Statistically significant (p < 0.05) 
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Table 2. Outcomes after 60 months follow-up (maximum) of the analytic cohort of subjects 
diagnosed with breast cancer between 2004 and 2016 in Kentucky. 
 
 
 
 
 
 
 
 
Table 3. Five most frequent second primary cancers among women in the breast cancer cohort 
(2004-2016). 
 
 
Kentucky  
N= 2,492 
Appalachia  
N= 646 
Non-Appalachia  
N= 1,846 
Breast 1,290 (51.77%) Breast 294 (45.51%) Breast 996 (53.95%) 
Lung and 
Bronchus 
291 (11.68%) Lung and 
Bronchus 
93 (14.40%) Lung and 
Bronchus 
198 (10.73%) 
Melanoma and 
skin  
77 (3.09%) Thyroid 26 (4.02%) Melanoma and 
skin 
61 (3.30%) 
Corpus Uteri 76 (3.05%) Corpus Uteri 21 (3.25%) Kidney and renal 
pelvis 
57 (3.09%) 
Kidney and renal 
pelvis 
71 (2.81%) Melanoma and 
skin 
16 (2.48%) Corpus Uteri 55 (2.98%) 
 Kentucky 
N= 31,058 
Appalachia  
N= 8,150 
Non-Appalachia  
N= 22,908 
p-value 
Recurrence 
No 
Yes  
 
29,045 (93.71%) 
2,013 (6.48%) 
 
7,640 (93.74%) 
510 (6.26%) 
 
21,405 (93.44%) 
1,503 (6.56%) 
 
0.34 
Multiple primaries 
No 
Yes 
 
28,566 (91.98%) 
2,492 (8.02%) 
 
7,504 (92.07%) 
646 (7.93%) 
 
21,062 (91.94%) 
1,846 (8.06%) 
 
0.71 
Table 4. Risk of multiple primaries and recurrence 2004-2016 (Univariate analysis) among women in the breast cancer cohort. 
 
 Multiple Primaries Recurrence 
Kentucky Appalachia Non-Appalachia Kentucky Appalachia Non-Appalachia 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Subtypes 
ER+ and 
PR+ 
ER+ Only 
PR+ Only 
ER- and PR- 
 
Ref 
 
0.88 (0.77,1.00) 
0.97 (0.66, 1.43) 
0.88 (0.79, 0.97) 
 
Ref 
 
1.01 (0.79, 1.28) 
1.61 (0.89,2.93) 
0.96 (0.78, 1.17) 
 
Ref 
 
0.83 (0.75,0.96) 
0.76 (0.46, 1.26) 
0.85 (0.75, 0.96) 
 
Ref 
 
1.83 (1.60, 2.08) 
2.61 (1.86, 3.65) 
2.70 (2.45, 2.97) 
 
Ref 
 
1.52 (1.17, 1.97) 
2.59 (1.39, 4.87) 
2.29 (1.88, 2.78) 
 
Ref 
1.95 (1.68, 2.27) 
2.61 (1.75, 3.89) 
2.85 (2.55, 3.19) 
Stage 
Localized 
Regional 
Distant 
Unknown 
 
Ref 
1.07 (0.98, 1.16) 
1.43 (1.20, 1.70) 
1.13 (0.60, 2.10) 
 
Ref 
1.02 (0.86, 1.21) 
1.43 (1.04, 1.98) 
0.73 (0.18, 2.94) 
 
Ref 
1.08 (0.98, 1.20) 
1.42 (1.15,1.76) 
1.30 (0.65, 2.60) 
 
Ref 
3.12 (2.85, 3.42) 
1.91 (1.48, 2.47) 
1.15 (0.43, 3.06) 
 
Ref 
2.54 (2.12, 3.03) 
1.60 (0.99, 2.59) 
1.74 (0.43, 6.98) 
 
Ref 
3.35 (3.02, 3.72) 
2.05 (1.52, 2.77) 
0.85 (0.21, 3.41) 
Family History 
No 
Yes 
Unknown 
 
Ref 
1.01 (1.004, 1.20) 
1.03 (0.93, 1.15) 
 
Ref 
0.99 (0.83,1.20) 
0.92 (0.76,1.12) 
 
Ref 
1.13 (1.02,1.25) 
1.08 (0.95,1.22) 
 
Ref 
0.95 (0.86, 1.04) 
0.80 (0.71, 0.91) 
 
Ref 
1.09 (0.88, 1.33) 
0.92 (0.74, 1.15) 
 
Ref 
0.91  (0.81, 1.02) 
0.75 (0.65, 0.88) 
Menopausal Status 
Pre 
 
Ref 
 
Ref 
 
Ref 
 
Ref 
 
Ref 
 
Ref 
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Post 
Unknown 
1.61 (1.44, 1.79) 
1.26 (1.09, 1.46) 
1.55 (1.25, 1.91) 
1.26 (0.96, 1.66) 
1.63 (1.44,1.86) 
1.26 (1.05, 1.50) 
0.74 (0.67, 0.82) 
0.71 (0.61, 0.82) 
0.71 (0.58, 0.86) 
0.69 (0.52, 0.91) 
0.75 (0.67, 0.84) 
0.71 (0.60, 0.85) 
Age at diagnosis 
< 35 
35 – 44 
45 – 54 
55 – 64 
65 – 74  
75 – 84 
85 + 
 
Ref 
0.94 (0.63, 1.41) 
1.31 (0.89, 1.92) 
1.63 (1.11, 2.37) 
2.26 (1.55, 3.30) 
2.44 (1.67, 3.58) 
2.31 (1.31, 3.38) 
 
Ref 
0.49 (0.23, 1.02) 
1.13 (0.59, 2.15) 
1.20 (0.64, 2.79) 
1.76 (0.94, 3.34) 
1.68 (0.88, 3.23) 
1.12 (0.50, 2.49) 
 
Ref 
1.18 (0.72, 1.95) 
1.42 (0.88, 2.28) 
1.86 (1.16, 2,98) 
2.54 (1.59, 4.06) 
2,86 (1.78, 4.59) 
2.89 (1.74, 4.79) 
 
Ref 
0.64 (0.51, 0.82) 
0.44 (0.35, 0.55) 
0.41 (0.32, 0.51) 
0.31 (0.24, 0.39) 
0.37 (0.29, 0.48) 
0.46 (0.33, 0.64) 
 
Ref 
0.67 (0.42, 1.08) 
0.50 (0.32, 0.79) 
0.45 (0.29, 0.70) 
0.34 (0.22, 0.55) 
0.38 (0.23, 0.65) 
0.25 (0.10, 0.61) 
 
Ref 
0.63 (0.48, 0.83) 
0.42 (0.32, 0.55) 
0.39 (0.30, 0.51) 
0.30 (0.23, 0.39) 
0.37 (0.27, 0.49) 
0.50 (0.35, 0.72) 
Tobacco user 
No 
Yes 
Unknown 
 
Ref 
1.41 (1.30, 1.54) 
1.10 (0.98, 1.24) 
 
Ref 
1.44 (1.22, 1.71) 
0.91 (0.72, 1.14) 
 
Ref 
1.41 (1.27, 1.55) 
1.20 (1.04, 1.37) 
 
Ref 
1.04 (0.94, 1.15) 
1.17 (1.04, 1.15) 
 
Ref 
1.13 (0.93, 1.38) 
1.07 (0.85, 1.36) 
 
Ref 
1.01 (0.90, 1.13) 
1.22 (1.06, 1.42) 
Insurance 
Insured 
Not Insured 
Medicaid 
Medicare 
Unknown 
 
Ref 
1.21 (0.91, 1.60) 
1.43 (1.23, 1.66) 
1.73 (1.59, 1.88) 
1.77 (1.17, 2.66) 
 
Ref 
1.21 (0.73, 1.98) 
1.46 (1.13, 1.88) 
1.81 (1.52, 2.16) 
2.01 (1.12, 3.61) 
 
Ref 
1.22 (0.87, 1.72) 
1.44 (1.20, 1.74) 
1.71 (1.57, 1.89) 
1.61 (0.89, 2.93) 
 
Ref 
1.29 (0.98, 1.68) 
1.56 (1.34, 1.80) 
0.91 (0.83,1.01) 
1.06 (0.61 ,1.84) 
 
Ref 
1.35 (0.87, 2.12) 
1.66 (1.31, 2.11) 
0.92 (0.75, 1.13) 
1.14 (0.54, 2.42) 
 
Ref 
1.40 (0.98, 1.99) 
1.54 (1.28, 1.84) 
0.91 (0.82, 1.02) 
1.03 (0.46, 2.29) 
• Bold: Statistically significant (p < 0.05) 
• HR: Hazard ratio 
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Table 5. Multivariable logistic regression analysis for predicting association between breast cancer subtypes and the outcomes 2004-
2016. Adjusted for family history, menopausal status, age at diagnosis, stage, tobacco use, and insurance status. 
 
 
 Multiple Primaries Recurrence 
Kentucky Appalachia Non-Appalachia Kentucky Appalachia Non-Appalachia 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Subtypes 
ER+ and 
PR+ 
ER+ Only 
PR+ Only 
ER- and PR- 
 
Ref 
 
0.85 (0.74, 0.96) 
1.05 (0.71, 1.54) 
0.94 (0.84, 1.04) 
 
Ref 
 
0.98 (0.77,1.25) 
1.71 (0.94, 3.12) 
1.03 (0.84, 1.26) 
 
Ref 
 
0.80 (0.69, 0.94) 
0.82 (0.49, 1.36) 
0.91 (0.80, 1.03) 
 
Ref 
 
1.75 (1.53, 1.99) 
2.38 (1.69, 3.33) 
2.44 (2.21, 2.69) 
 
Ref 
 
1.49 (1.15, 1.95) 
2.47 (1.31, 4.66) 
2.07 (1.99, 3.13) 
 
Ref 
 
1.84 (1.58, 2.14) 
2.30 (1.54, 3.43) 
2.58 (2.31, 2.89) 
• Bold: Statistically significant  
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Table 6. Distribution of the exposure of interest among women in the breast cancer cohort (2011-2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Kentucky 
N= 15,371 
Appalachia  
N= 3,997 
Non-Appalachia  
N= 11,374 
p-
value 
Subtypes 
Luminal A 
Luminal B 
HER2 enriched 
Triple Negative 
Other  
 
10,554 (68.66%) 
1,574 (10.24 %) 
719 (4.68%) 
1,826 (11.88%) 
698 (4.54%) 
 
2,643 (66.12%) 
429 (10.73%) 
207 (5.18%) 
512 (12.81%) 
206 (5.15%) 
 
7,911 (69.55%) 
1,145 (10.07%) 
512 (4.50%) 
1,314 (11.55%) 
492 (4.33%) 
 
 
0.0014 
• Luminal A: ER+ and/or PR +, HER2- 
• Luminal B:  ER+ and/or PR +, HER2+ 
• HER2 enriched: ER-, PR-, HER2+ 
• Triple negative: ER-, PR-, HER2- 
• Other: Borderline result, one or more test(s) not performed, not documented  
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Table 7. Multivariable logistic regression analysis for predicting association between breast cancer subtypes and the outcomes 2011-
2016. Adjusted for family history, menopausal status, age at diagnosis, stage, tobacco use, and insurance status. 
 
 Multiple Primaries Recurrence 
Kentucky 
(Overall)  
Appalachia Non-
Appalachia 
Kentucky 
(Overall) 
Appalachia Non-Appalachia 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Subtypes 
Luminal A 
Luminal B 
HER2 enriched 
Triple Negative 
Other 
 
Ref 
0.82 (0.66, 1.02) 
0.87 (0.64, 1.18) 
0.85 (0.70,1.04) 
1.29 (1.01,1.65) 
 
Ref 
0.97 (0.65, 1.43) 
1.09 (0.65, 1.86) 
0.94 (0.68, 1.40) 
1.13 (0.69, 1.84) 
 
Ref 
0.76 (0.59,0.99) 
0.77 (0.45, 1.31) 
0.81 (0.64, 1.03) 
1.37 (1.02, 1.83) 
 
Ref 
1.61 (1.28,2.03) 
2.09 (1.57, 2.80) 
3.16 (2.64, 3.79) 
0.99 (0.63, 1.530 
 
Ref 
1.42 (0.89, 2.29) 
1.03 (0.49, 2.15) 
2.76 (1.91, 3.98) 
1.21 (0.58, 2.51) 
 
Ref 
1.69 (1.29, 2.20) 
2.57 (1.87, 3.53) 
3.35 (2.72, 4.13) 
0.88 (0.50, 1,54) 
• Bold: Statistically significant  
• Luminal A: ER+ and/or PR +, HER2- 
• Luminal B:  ER+ and/or PR +, HER2+ 
• HER2 enriched: ER-, PR-, HER2+ 
• Triple negative: ER-, PR-, HER2- 
• Other: Borderline result, one or more test(s) not performed, not documented 
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Figure 3 
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Figure 5. 
 
 
 
 
 
Figure 6 
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